|
Efficacy of 3 Day
Azithromycin Versus 10 Day Co-Amoxiclav in the
Treatment of Children with Acute Otitis Media
.........................................................................................................................
Khaled Amro, MD*
*Pediatrician from department of pediatric
In Royal Medical Services-Jordan
|
ABSTRACT
Objective:
To compare the use of Azithromycin and
co-Amoxiclav in the treatment of symptoms
and signs of acute suppurative otitis
media in children.
Methods:
Children of four months to 12 years of
age, attended out-patient Pediatric and
ENT clinics at Prince Hashim bin Al Hussain
Hospital in AZ-Zarqa (JORDAN) from June
2006 to June 2007; with signs and symptoms
of acute suppurative otitis media, were
enrolled in the study. Patients were randomized
to receive either Azithromycin 10 mg/kg/day
in a single dose for 3 days or co-Amoxiclav
45 mg/kg/day in three divided doses for
10 days. Clinical improvement was evaluated
on the 2nd and 4th weeks after therapy.
Results:
Satisfactory clinical response was measured
regarding symptoms and signs two weeks
after the beginning of therapy. They were
84.6% for Azithromycin and 88% for Co-Amoxiclav.
At day 28, 61 patients (82.4%) were cured
on Azithromycin compared with 66 patients
(83.5 %) on Co-Amoxiclav.
Conclusion:
Azithromycin given for three days and
Co-Amoxiclav for ten days had similar
efficacy; however, Azithromycin was better
tolerated.
Key
words: Acute Suppurative Otitis Media,
Children, Antibiotics.
|
Otitis Media is an inflammation
in the middle ear. Subcategories include acute
otitis media, otitis media with effusion (also
known as "glue ear"), recurrent acute
otitis media, and chronic suppurative otitis
media. Acute otitis media presents with systemic
and local signs and has a rapid onset. The persistence
of an effusion beyond three months without signs
of infection defines otitis media with effusion,
whereas chronic suppurative otitis media is
characterized by continuing inflammation in
the middle ear giving rise to otorrhoea and
a perforated tympanic membrane(1).
Our study is on Acute Suppurative
Otitis Media (ASOM), which is a suppurative
infection of the middle ear cavity and is most
common in healthy children between 6 months
and 2 years of age, it is more common in boys,
in patients of lower socioeconomic status, in
formula fed infants, and in the winter months(2).
It is an important health problem in early childhood,
and is the most frequent condition for which
antibiotics are prescribed in the USA(3).
The most common pathogens
are streptococcus pneumonic Hemophilus Influenza,
and Branhamella catarrhal; half of these organisms
are B-lactamase producers. Very young children
will not complain of pain but will be irritable
and may bang the head on the cot sides. On examination,
the young child is febrile, restless and uncooperative
with red, bulging tympanic membrane. If the
ears discharge, it is usually blood stained
initially and this may worry parents.
The discharge then becomes
mucopurulent(4). A combination of
important factors contributes to pathogenesis
of ASOM. The most two important factors in children
are Eustachian tube dysfunction and the child
susceptibility to recurrent upper respiratory
tract infections. In the child, the Eustachian
tube is shorter (less distance for organisms
to travel), placed horizontal (inadequate drainage
of middle ear) and has adenoids present at the
opening, which can readily block the tube and
serve as a reservoir of infection.
Bacteria are responsible
for the majority of cases(5). Antibiotic
treatment of Acute Suppurative Otitis Media
hastens symptomatic relief and potentially prevents
the development of more serious invasive disease(6).
As there are a number of antibiotics used for
this purpose we undertook this trial in children
with ASOM to compare the use of two important
antibiotics commonly used in this condition
in Jordan.
Amoxicillin semi synthetic
penicillin has broadened spectra against Gram-negatives
and is effective orally. Amoxicillin plus Clavulanate
is Clavamox or Augmentin. The Clavulanate is
not an anti- microbial agent; it inhibits beta-lactamase
enzymes and has given extended life to penicillinase(7).
Generally ampicillin, amoxicillin, or co-Amoxiclav
(amoxicillin-clavulanate) are preferred and
most commonly used in ASOM in Jordan.
Azithromycin is an azolide
antibiotic. It is active in vitro against a
variety of microorganisms and has a greater
distribution in tissues, a longer elimination
half-life and a lower incidence of adverse effects
than Erythromycin(8). The purpose
of this study was to compare the clinical use
of Azithromycin with Amoxiclav.
This consecutive study was carried out at PrinceHashim
Hospital in AZ-Zarqa city in Jordan from June
2006 to June 2007, on children attending outpatient
ENT and pediatric OPD clinics. Children of ages
four months to twelve years were enrolled in
the study, if they satisfied one or more of
the following criteria:
- Ear pain or fullness.
- Decreased hearing.
- Discharge from the external auditory canal.
- Bulging or marked injection of the tympanic
membrane.
- Loss of the normal light reflex or tympanic
membrane landmarks.
- As well as generalized symptoms; fever,
general malaise, and irritability.
Exclusion criteria included: History of Macrolide
or B-lactamase drug allergy, history of antibiotic
treatment in the preceding four weeks, Symptoms
persisting for more than four weeks, and children
receiving antimicrobial prophylaxis.
Patients were randomized on alternative weeks
and accordingly divided into two groups: First
group received either Azithromycin (10 mg/kg/day)
once daily for three days, and second group
were given Co-Amoxiclav (45mg/kg/day) in three
divided doses for ten days.
Assessment of these patients was carried out
on the initial visits and follow up was done
on days 14 and 28.
Patients were identified to be cured when there
was a complete resolution of all signs and symptoms,
improved by partial resolution of signs and
symptoms, and failed, if there were no changes
or worsening of symptoms and signs.
On follow up visits complete Ear, Nose and
Throat examination was performed by the same
physicians at all pre treatment and post treatment
visits.
Two hundred and three patients were initially
enrolled in the study. 17 patients were non-eligible
as 5 had allergy to Amoxicillin, and 12 didn't
fulfill the inclusion criteria because they
received antibiotics in the preceding four weeks.
The total number of patients found eligible
in our study was 186 children. All of these
patients were randomized into two groups; the
first group included 91 children (received Azithromycin
10mg/kg/day once daily for three days), while
the second group included 95 children and were
given Co-Amoxiclav 45 mg/kg/day in three divided
doses for 10days). The mean age of patients
enrolled was 3.4 years (range 4 months-12 years).
The most common symptom was ear pain (94%)
while the most common sign was of injection
tympanic membrane (93%). (Table I) Patients'
post treatment evaluation was done at two weeks;
in the first group, 66 out of 78 children (84.6%)
showed improvement or were cured, compared to
74 out of 84 children (88%) in the second group.
However, at four weeks post treatment, 61 out
74 children (82.4%) in the first group were
completely cured and did not need any further
antibiotic treatment, compared again to 66 out
of 69 children (83.5%) in the second group.
(Table II, Figure 1)
Regarding the adverse effects to the drugs
used, these were mostly seen in children treated
with Co-Amoxiclav compared with those who received
Azithromycin and occurred in18% and 10% respectively.
The most commonly observed side effect with
both drugs was diarrhea. Rash and vomiting were
also seen.
| Table
1: Signs and symptoms found at presentation |
|
Signs
and symptoms |
Number |
% |
|
Ear
pain or fullness |
175 |
94 |
|
Decrease
hearing |
23 |
12.3 |
|
Discharge
from external auditory canal |
13 |
7 |
|
Injection
of tympanic membrane |
172 |
93 |
|
Bulging
of tympanic membrane |
98 |
47.8 |
|
Perforated
tympanic membrane |
9 |
4.8 |
|
Generalized
symptoms, fever, general malaise and irritability |
69 |
37 |
| Table
2: Response after two and four weeks |
| |
Azithromycin |
% |
Co-Amoxiclav |
% |
|
Response
at two weeks cured and/or improved |
66/78 |
84.6 |
74/84 |
88 |
|
Response
at four weeks cured and/or improved |
61/74 |
82.4 |
66/79 |
83.5 |
Fig. 1 Total number of patients

In Jordan, particularly the Royal Medical
Services, Acute Suppurative Otitis Media is
usually treated with antibiotics, and generally
amoxicillin, or Co-Amoxiclav (amoxicillin-clavulanate)
are preferred and this depends on the availability
and the cost of these medications. In his study,
Dunne MW et al have provided evidence that Azithromycin
for three days of treatment with a total dose
of 30 mg/kg/day is as effective as Co-Amoxiclav
given at 45 mg/kg/day. Similarly our study carried
out on children of various age groups showed
that the success rate of treatment at 2 and
4 weeks was nearly equivalent for both antibiotics
and there was no significant difference (Table
II).
Satisfactory clinical response regarding symptoms
and signs evaluated at 2 weeks post treatment
was 84.6% for Azithromycin and 88% for Co-Amoxiclav;
this is compared to results seen in the Dunne
et al study where the clinical success (cure
and improvement) in all subjects was 83% for
Azithromycin group of patients, and 88% for
patients on Co-Amoxiclav on evaluation at 10
days post treatment. However regarding Co- Amoxiclav,
it was noted that it led to a quicker resolution
of tympanic membrane signs such as bulging and
loss of landmarks at two weeks after initiation
of treatment, whereas at four weeks of treatment
both agents showed a similar outcome.
As for the mechanism of action, Co-Amoxiclav
is a bactericidal agent whereas Azithromycin
is a protein synthesis inhibitor (bacteristatic)
agent; it is an azolide antibiotic, which has
a greater distribution in tissues, a longer
elimination half-life, and a lower incidence
of adverse effects, than erythromycin. These
pharmacokinetic features allow once-daily dosing
and a shorter duration of therapy(9,10).
Our diagnoses were based on acute signs of
infection and eardrum abnormalities, which is
in keeping with the day-to-day practice in our
hospital (The Royal Medical Services). There
is a considerable controversy as to what antibiotic
to use if at all, as some studies showed that
up to 80% of cases with ASOM would resolve within
one week without antibiotic treatment. The generalized
use of antibiotics in this condition increases
health care costs and creates numerous side
effects(10). Watchful waiting at
the first visit was justified by Damoiseaux
et al for children aged 6-24 months with ASOM(11),
and Froom et al state that the Netherlands is
the only country where only a minority of the
episodes of Otitis Media are treated with antibiotics.
The outcome of ASOM does not seem to be any
worse than in other countries. In addition,
doctors are often uncertain about the diagnosis
of Suppurative Otitis Media. Therefore, we recommend
that clinicians should immediately reconsider
the routine use of antimicrobials for children
with Suppurative Otitis Media and consider treating
symptoms with analgesics and observation for
lack of improvement(12). In conclusion,
azithromycin given for three days and co-Amoxiclav
for 10 days had similar efficacy; however, Azithromycin
was better tolerated.
- O'Neill P.Clinical evidence: Acute otitis
media. BMJ1999; 319:833-835.
- Prince A. Infections Diseases. In: Behrman
RE, Kliegman RM, editors. Nelson essential
of pediatrics. 4th edition, Saunders WB, USA.
2001; 10: 388-389.
- Arrieta A, Arguedas A, Fernandez P, et
al. High-dose azithromycin versus high-dose
amoxicillinclavulanate for treatment of children
with recurrent or persistent acute otitis
media. Antimicrob Agents Chemother2003; 47(10):
3179-3186.
- Kerr AG. Acute otitis media. In: Adams DA,
Cinnamond MJ, editors. Scott-Brown's Otolaryngology.
6th edition, Arnold. 1996; 8: 220-221.
- Jacob A, Rupa V, Job A, Joseph A. Hearing
impairment and otitis media in a rural primary
school in south India. Int J Pediar Otohinolaryngol1997;
39(2): 133-138.
- Dunne MW, Latiolais T, Lewis B, et al.
Randomized, double-blind study of the clinical
efficacy of 3 days of azithromycin compared
with co-amoxiclav for the treatment of acute
otitis media. J Antimicrob Chemother 2003;
52(3): 469-472.
- Kennell Toda. University of Wisconsin-Madison,
Department of Bacteriology. 2002
- Foulds G, Shepard RM, Johnson RB, et al.
The pharmacokinetics of Azithromycin in human
serum and tissues. J Antimicrob Chemother1990;
25:73-82.
- Nahata MC, Koranyi KI, Luke DR, Foulds G.Pharmacokinetics
of azithromycin in pediatric patients with
acute otitis media. Antimicrobial Agents Chemotherapy1995;
39(8): 1875-1877.
- Parra A, Ponte C, Cenjor C, et al. Effect
of antibiotic treatment delay on therapeutic
outcome of experimental acute otitis media
caused by Streptococcus pneumoniae strains
with different susceptibilities to amoxicillin.
Antimicrobial Agents Chemotherapy2004; 48(3):
860-866.
- Damoiseaux RAMJ, Van Balen FAM, Hoes AW,
et al. Primary care based randomised, double
blind trial of amoxicillin versus placebo
for acute otitis media in children aged under
2 years.BMJ2000; 320: 350-354.
- Froom J, Culpepper L, Grob P, et al. Diagnosis
and antibiotic treatment of acute otitis media:
Report from International Primary Care Network.
BMJ 1990; 300: 582-586.
|